stockrow
Monday 9 November 2026
Export EVMN’s income statement to Excel — free account
Evommune Inc.
EVMNEvommune Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 85.7% from fiscal 2024.
- EPS
- +89.9%
- Free cash flow
- +21.8%
Quarter to June 2026, against a year earlier
6.65
0.28
+4.40%
Follow EVMN
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+4 more quarters Free account |
0.00 | — | — | — |
P/S ratio |
0.00 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(3.24) | — | — | — | |
P/B ratio |
0.00 | — | — | — | |
Price to Tangible BV |
0.00 | — | — | — | |
EV/Sales |
0.00 | — | — | — | |
EV/EBITDA |
0.67 | — | — | — | |
EV/Operating CF |
0.57 | — | — | — | |
EV/FCF |
0.57 | — | — | — | |
Quick Ratio |
7.30 | 8.33 | 19.94 | 11.48 | |
Current Ratio |
7.87 | 8.57 | 20.36 | 11.68 | |
Net Debt/EBITDA |
6.16 | 5.07 | 8.65 | 5.71 | |
Debt/Assets |
0.00% | 0.08% | 0.16% | 0.14% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.59 | 1.27 | 0.63 | |
Capex/Depreciation |
(0.13) | (0.32) | 0.19 | 0.90 | |
Research and Development Expense of Revenue |
196.39% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
36.89% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.60% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(5.94) | — | — | — | |
Graham Number |
313.37 | — | — | — | |
Earnings Yield |
(182.01%) | — | — | — | |
Free Cash Flow Yield |
(250.37%) | — | — | — | |
Revenue per Share |
6.47 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(6.24) | (2.72) | (0.82) | (0.56) | |
Capex per Share |
(0.08) | (0.02) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(6.32) | (2.74) | (0.82) | (0.57) | |
Cash per Share |
49.23 | 24.31 | 6.28 | 5.56 | |
Shareholders Equity per Share |
(118.54) | 33.50 | 9.05 | 7.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(118.54) | 33.50 | 9.05 | 7.68 | |
Free Cash Flow |
(9.77) | (16.80) | (27.59) | (20.50) | |
Working Capital |
71.53 | 135.57 | 205.25 | 186.76 | |
Capital Expenditures |
(0.13) | (0.10) | (0.08) | (0.18) | |
Net Current Asset Value |
(185.74) | 134.10 | 197.96 | 179.89 | |
EV/EBIT |
0.66 | — | — | — | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Payables |
— | — | — | 6.65 | |
Average Assets |
42.27 | 112.47 | 161.23 | 150.97 | |
Average Common Equity |
— | — | — | 66.67 |
Columns are period end dates · fundamentals updated 25 Oct 2026